AMVUTTRA® safety and tolerability profile

Adverse reactions reported in at least 5% of patients treated with AMVUTTRA1
Pain in extremitya 15
Arthralgiaa 11
Dyspneaa 7
Vitamin A decreasedb 7

aComprised of several similar terms.

bPercentage only reflects those reported as an adverse reaction.

aExternal placebo group from APOLLO. Mean duration of exposure was 15 months (range: 1.3-18.8 months).

bIncludes dyspnea, dyspnea exertional, and dyspnea paroxysmal nocturnal.

  • The safety profile of AMVUTTRA was generally consistent across all subgroups2,c
  • There were no drug-related discontinuations or deaths in patients treated with AMVUTTRA3
  • Injection site reactions occurred in 4% of patients and were mild and transient1,3
  • There are no contraindications for AMVUTTRA1

cSubgroups included age, sex, V30M variant status, previous TTR stabilizer use, and disease stage.2


Clipboard check icon
Starting treatment
Find out how to get your patients started with AMVUTTRA.
Circle check icon
Stay informed
Receive relevant content and updates.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).


AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.


  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Data on file. Alnylam Pharmaceuticals, Inc.
  3. Adams D, Tournev IL, Taylor MS, et al. Amyloid. 2022. Published online July 23, 2022.